A recent review takes a closer look at the complex and still-evolving relationship between hereditary alpha-tryptasemia (HαT) and mastocytosis, two conditions linked by mast cell biology and the biomarker tryptase. The paper, published in Current Allergy and Asthma Reports, summarizes current knowledge about how the genetic trait HαT may influence the diagnosis and clinical presentation of mast cell disorders.
Hereditary alpha-tryptasemia is a genetic trait caused by extra copies of the TPSAB1 gene. This gene produces alpha-tryptase, a protein released by mast cells. An elevated serum tryptase level is a key diagnostic marker for mast cell disorders, including systemic mastocytosis (SM).
People with HαT typically have higher-than-average levels of tryptase in their blood. While many with the genetic trait do not develop serious health problems, the elevated tryptase levels can influence how doctors evaluate possible SM.
Researchers have found that HαT appears more frequently in people with mastocytosis than in the general population. While about 5% to 7% of people overall carry the genetic trait, studies suggest that roughly 15% to 20% of those with mastocytosis may have HαT. Scientists are still working to understand why these two conditions often occur together.
Learn more about SM causes and risk factors
One possible explanation is related to testing. Because HαT naturally causes higher baseline tryptase levels, it can prompt additional diagnostic procedures, such as bone marrow biopsies, and increase the likelihood of detecting mastocytosis.
At the same time, genetically elevated levels may mimic mast cell disease or obscure signs of mast cell activation. This can lead to uncertainty in clinical assessment or unnecessary invasive testing.
Some studies have also suggested that HαT may influence symptoms in mast cell disorders, particularly increasing the risk of severe reactions such as anaphylaxis in certain patients. However, findings have been inconsistent, and researchers caution that the relationship is not fully understood.
“Future population-based studies employing ultra-sensitive molecular techniques and stratified analyses are needed to elucidate the biological and clinical significance of HαT in mast cell disorders,” the researchers concluded.
Sign up here to get the latest news, perspectives, and information about SM sent directly to your inbox. Registration is free and only takes a minute.
